Conference Coverage
Latest News
Sep 22, 2026 | News
Network meta-analysis ranks neoadjuvant options in cisplatin-eligible MIBC
Chemoablation expands treatment options for recurrent LG-IR-NMIBC
Sep 22, 2026
Eugene Cone, MD, discusses recombinant BCG in NMIBC
Sep 21, 2026
Use of prebiopsy prostate MRI increasing across US hospitals, study finds
Sep 21, 2026
FDA grants breakthrough device designation to urine ID/AST panel
Sep 21, 2026
Advertisement
Shorts
1:17
Neoadjuvant therapy before prostatectomy: Assessing functional outcomes
2 hours ago
by
Adam B. Weiner, MD(+1 more)
0:40
How unequal PSMA-PET access may affect prostate cancer care
a day ago
by
Juan Gómez Rivas, MD, FEBU, PhD
0:33
What a positive NeoBLAST trial would mean for MIBC care
4 days ago
by
Marie-Pier St-Laurent, MD, FRCSC
0:43
Why independent urology practices face growing pressure
5 days ago
by
Celeste Kirschner, CAE, MHSA
1:33
The long-term cost question behind OAB drug selection
6 days ago
by
Anjali Kapur, MD
0:51
How to spot patients chasing a product, not a diagnosis
7 days ago
by
Jean Cunningham, PharmD, BCPS
0:24
How NeoBLAST defines and confirms complete response
8 days ago
by
Marie-Pier St-Laurent, MD, FRCSC
1:09
Considering the practical benefits of intraoperative chemotherapy at nephroureterectomy
11 days ago
by
Adam B. Weiner, MD(+1 more)
0:22
What the evidence says on penile cancer margin management
12 days ago
by
Luis G. Medina, MD
0:21
4 steps to implementing a rapid access model for elevated PSA
13 days ago
by
Zach Feuer, MD
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
A decision is expected by the fourth quarter of 2026.
Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
The clearance expands access to the LigaSure vessel-sealing technology within robotic surgical workflows.
Early neurophysiology and pressure-flow research directly underpin modern urodynamics, whereas Turner-Warwick's restorative philosophy, according to Sasha Vereecken, BScN, RN.
These FAQs outline key recommendations and practical takeaways from the 2026 AUA Medical Management of Kidney Stones guideline amendment.
Advertisement
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
A phase 1 study found topical sildenafil cream was linked with lower systemic exposure than oral sildenafil and was well tolerated in healthy men.
Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
Advertisement
Advertisement
Trending on Urology Times
1
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
2
FDA grants breakthrough device designation to urine ID/AST panel
3
Use of prebiopsy prostate MRI increasing across US hospitals, study finds
4
Eugene Cone, MD, discusses recombinant BCG in NMIBC
5